| Literature DB >> 31234430 |
Yi-Ping Yang1,2,3, Phan Nguyen Nhi Nguyen4,5, Tai-Chi Lin6,7,8, Aliaksandr A Yarmishyn9,10, Wun-Syuan Chen11, De-Kuang Hwang12,13,14, Guang-Yuh Chiou15, Tzu-Wei Lin16, Chian-Shiu Chien17,18, Ching-Yao Tsai19,20, Shih-Hwa Chiou21,22,23, Shih-Jen Chen24,25, Chi-Hsien Peng26,27, Chih-Chien Hsu28,29.
Abstract
The mitochondrial genetic disorder, Leber's hereditary optic neuropathy (LHON), is caused by a mutation in MT-ND4 gene, encoding NADH dehydrogenase subunit 4. It leads to the progressive death of retinal ganglion cells (RGCs) and causes visual impairment or even blindness. However, the precise mechanisms of LHON disease penetrance and progression are not completely elucidated. Human-induced pluripotent stem cells (hiPSCs) offer unique opportunities to investigate disease-relevant phenotypes and regulatory mechanisms underlying LHON pathogenesis at the cellular level. In this study, we successfully generated RGCs by differentiation of LHON patient-specific hiPSCs. We modified the protocol of differentiation to obtain a more enriched population of single-cell RGCs for LHON study. Based on assessing morphology, expression of specific markers and electrophysiological activity, we found that LHON-specific hiPSC-derived were more defective in comparison with normal wild-type RGCs. Based on our previous study, whereby by using microarray analysis we identified that the components of glutamatergic synapse signaling pathway were significantly downregulated in LHON-specific RGCs, we focused our study on glutamate-associated α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors. We found that the protein expression levels of the subunits of the AMPA receptor, GluR1 and GluR2, and their associated scaffold proteins were decreased in LHON-RGCs. By performing the co-immunoprecipitation assay, we found several differences in the efficiencies of interaction between AMPA subunits and scaffold proteins between normal and LHON-specific RGCs.Entities:
Keywords: AMPA receptor; Leber’s hereditary optic neuropathy (LHON); glutamate; retina; retinal ganglion cell
Mesh:
Substances:
Year: 2019 PMID: 31234430 PMCID: PMC6627514 DOI: 10.3390/cells8060625
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Characterization of Leber’s hereditary optic neuropathy (LHON) patient. (A) Fundus photography showing temporal pallor of optic disc in both eyes. (B) Visual filed test showing bilateral central scotoma with mean deviation of −9.12 dB in the right eye and of −8.25 dB in the left eye. (C) Optical coherence tomography showing decreased peripapillary average retinal fiber layer thickness of 63 μm and 59 μm in right and left eye, respectively. (D) Optical coherence tomography showing thinning of macular ganglion cell layers in both eyes. (E) DNA sequencing demonstrating the presence of G11778A mutation in patient’s mtDNA.
Figure 2Differentiation of human-induced pluripotent stem cells (hiPSCs) from retinal ganglion cells (RGCs). (A) Schematic showing the timeline and procedure of differentiation of RGCs from hiPSCs by using the original and modified single-cell methods. (B) Bright field images of 2-day and 12-day normal hiPSC-derived RGCs obtained by the original and single-cell methods. (C) Immunostaining of RGC marker TuJ1 in the normal hiPSC-derived RGCs obtained by both methods. (D) Flow cytometry analysis of the proportion of CD90-expressing 21-day normal hiPSC-derived RGCs obtained by both methods. (E) Western blot showing expression of glial marker GFAP in the population of 21-day normal hiPSC-derived RGCs obtained by both methods. (F) qRT-PCR analysis of expression of neuronal/RGC markers and pluripotency marker NANOG in a time course of differentiation of hiPSCs to RGCs at the indicated stages. The mean fold change relative to hiPSC from three biological replicates is shown with standard deviation error bars. EB—embryoid body, NR—neural rosette, OV—optic vesicle, RGC—retinal ganglion cell, hiPSC—human-induced pluripotent stem cell. * p < 0.05 (Student’s t-test) as compared to hiPSC. (G) Immunostaining showing expression of RGC-specific markers BRN3a, NFM, ATOH7 and TuJ1 in 21-day normal RGCs obtained by single-cell method. Nuclei stained with DAPI. Scale bar: 20 µm.
Figure 3Enriched single-cell LHON-RGC population recapitulates LHON pathological features. (A) Bright field images showing morphologies of wild type (normal) and LHON-specific hiPSCs, EBs, NRs, OVs, and 2-day RGCs. Scale bar: 100 µm. (B) Western blot showing protein expression level of TuJ1 in OVs and RGCs derived from normal and LHON-specific hiPSCs. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) used as a loading control. (C) Electrophysiological analysis of day-21 Normal-RGCs and LHON-RGCs. Patch clamp was used to detect the spikes of action potential of cells submerged in tetrodotoxin-free artificial cerebrospinal fluid (ACSF) and ACSF containing 0.5 μM tetrodotoxin for negative control (TTX). * p < 0.05, ** p < 0.01.
Figure 4α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors and AMPA scaffold proteins are downregulated in LHON-RGCs. (A) Schematic showing KEGG pathway “Glutamatergic synapse” with the genes downregulated in LHON-RGCs marked with asterisks. (B) ELISA measurement of glutamate secreted by 7-day and 14-day Normal-RGCs and Control-RGCs. Mean concentrations from three independent measurements are shown with standard deviation error bars. (C) Western blot analysis demonstrating expression of GluR1 and GluR2 in day-3, day-7 and day-14 Normal-RGCs and LHON-RGCs. GAPDH used as a loading control. (D) Quantification of Western blot expression levels of GluR1 and GluR2. Means from three independent experiments are shown with standard deviation error bars. ** p < 0.01, * p < 0.05. (E) Immunofluorescent staining of GluR2 in Normal-RGCs and LHON-RGCs. Signal intensity was quantified by ImageJ and shown below. Nuclei stained with DAPI, neurites–by immunostaining of F-actin. (F) Western blot analysis of expression of AMPA receptor-associated scaffold proteins in Normal-RGCs and LHON-RGCs at different stages of maturity. GAPDH used as a loading control.
Figure 5Protein–protein interactions between AMPA receptors and their associated scaffold proteins in LHON-RGCs. (A) Western blot analysis of PICK1, Parkin and GRIP1 immunoprecipitates from lysates of 21-day Normal-RGCs and LHON-RGCs (right panel). The aliquots of total lysates were analyzed in parallel (left panel). (B) Quantification of signal intensity in the indicated immunoprecipitates using ImageJ. The signal of protein binding was normalized to the signal of immunoprecipitated protein.
Figure 6Effects of glutamate stimulation on the expression of AMPA receptors in LHON-RGCs. (A) Immunoblot analysis of the effect of treatment of Normal-RGCs and LHON-RGCs with 10 μM glutamate for the indicated time periods on expression levels of AMPA receptors and PINK1 and Parkin scaffold proteins. GAPDH used as a loading control (B) The protein expression level of GluR1/R2, PINK1 and Parkin in Normal- and LHON-RGCs were quantified by Image J.
Figure 7Trafficking of AMPA receptors in LHON-RGCs under glutamate stimulation. Immunofluorescent staining of surface and intracellular GluR1 in Normal-RGCs and LHON-RGCs in the absence (A) and presence (B) of glutamate stimulation. The immunofluorescence signal intensities were quantified by ImageJ (right panels). * p < 0.01, ** p < 0.001.